Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2012 Jul-Aug;4(4):419-25.
doi: 10.4161/mabs.20996. Epub 2012 Jul 1.

Marketing approval of mogamulizumab: a triumph for glyco-engineering

Alain Beck, Janice M Reichert
Editorial

Marketing approval of mogamulizumab: a triumph for glyco-engineering

Alain Beck et al. MAbs. 2012 Jul-Aug.

Abstract

Therapeutic properties of antibodies strongly depend on the composition of their glycans. Most of the currently approved antibodies are produced in mammalian cell lines, which yield mixtures of different glycoforms that are close to those of humans, but not fully identical. Glyco-engineering is being developed as a method to control the composition of carbohydrates and to enhance the pharmacological properties of mAbs. The recent approval in Japan of mogamulizumab (POTELIGEO (®) ), the first glyco-engineered antibody to reach the market, is a landmark in the field of therapeutic antibodies. Mogamulizumab is a humanized mAb derived from Kyowa Hakko Kirin's POTELLIGENT (®) technology, which produces antibodies with enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) activity. The approval was granted April 30, 2012 by the Japanese Ministry of Health, Labour and Welfare for patients with relapsed or refractory CCR4-positive adult T-cell leukemia-lymphoma.

PubMed Disclaimer

Figures

None
Figure 1. IgG antibody N-glycosylation
None
Figure 2. Antibody glycosylation: human, recombinant and glyco-engineered
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Paz-Ares LG, Gomez-Roca C, Delord JP, Cervantes A, Markman B, Corral J, et al. Phase I pharmacokinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor, in patients with advanced solid tumors. J Clin Oncol. 2011;29:3783–90. doi: 10.1200/JCO.2011.34.8888. - DOI - PubMed
    1. Beck A, Wagner-Rousset E, Bussat MC, Lokteff M, Klinguer-Hamour C, Haeuw JF, et al. Trends in glycosylation, glycoanalysis and glycoengineering of therapeutic antibodies and Fc-fusion proteins. Curr Pharm Biotechnol. 2008;9:482–501. doi: 10.2174/138920108786786411. - DOI - PubMed
    1. Reichert JM. Marketed therapeutic antibodies compendium. MAbs. 2012;4:413–5. doi: 10.4161/mabs.19931. - DOI - PMC - PubMed
    1. Jefferis R. Isotype and glycoform selection for antibody therapeutics. Arch Biochem Biophys. 2012 doi: 10.1016/j.abb.2012.03.021. In press. - DOI - PubMed
    1. Raju TS, Jordan RE. Galactosylation variations in marketed therapeutic antibodies. MAbs. 2012;4:385–91. doi: 10.4161/mabs.19868. - DOI - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources